“Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo in scalp, nail, and palmoplantar psoriasis: subset analyses of the phase 3 POETYK PSO-1 and PSO-2 trials” (2022) SKIN The Journal of Cutaneous Medicine, 6(4), p. s41. doi:10.25251/skin.6.supp.41.